2015-2017年江苏省东台市疑似预防接种异常反应监测结果分析
|
摘要
目的 2015-2017年分析江苏省东台市疑似预防接种异常反应的分布特征,为科学处置AEFI提供依据。方法对2015-2017年东台市AEFI报告个案、疫苗预防接种数据进行描述性分析。结果 2015-2017年东台市共报告AEFI病例586例,报告发生率95. 05/10万剂。症状发生至调查时间间隔≤48小时及时率90. 96%。AEFI报告时间集中于第2、3季度,男女性别比1. 37∶1,中位年龄1. 54岁,各地区报告发生率0/10万剂～258. 46/10万剂之间,NIP疫苗报告发生率(/10万剂)高于非NIP疫苗(/10万剂);各疫苗AEFI报告发生率之间差异明显。AEFI以一般反应(86. 18%)为主,异常反应占12. 46%,临床症状以发热、红肿、硬结、过敏性皮疹为主,报告发生率分别为53. 69/10万剂、35. 85/10万剂、17. 36/10万剂、10. 87/10万剂。AEFI发生时间与疫苗接种时间间隔以48小时内(87. 21%)为主。结论 2015-2017年东台市AEFI报告发生率高于全国水平,但一般反应灵敏度不高,报告地区间、各疫苗间AEFI监测报告平衡性有待进一步提高。
Objective To analyze the distribution features of suspected adverse events following immunization( AEFI) from 2015 to 2017 in Dongtai City,Jiangsu Province,and to provide a basis for the scientific disposal of AEFI. Methods The AEFI report cases and vaccination data of Dongtai from 2015 to 2017 were analyzed in a descriptive approach. Results A total of 586 cases of AEFI were reported in Dongtai City from 2015 to 2017,with a reported incidence rate of 95. 05/100 000 doses. The timely rate that the interval of symptoms occurred until the investigation within 48 hours was 90. 96%. The AEFI report was concentrated in the second and third quarters,with the male-female ratio of 1. 37 ∶ 1 and the median age of 1. 54 years. The reported rates in different regions were between 0 and 258. 46/100 000 doses,and the reported incidence rate of AEFI about NIP vaccines was higher than that of other vaccines,and the reported incidence rate of each vaccine was significantly different. Of all the AEFIs,86. 18% were general reactions,and adverse events accounted for 12. 46%. The clinical symptoms were mainly fever,redness,swelling,induration and allergic rash. The reported rates were 53. 69/100 000 doses,35. 85/100 000 doses,17. 36/100 000 doses and 10. 87/100 000 doses,respectively. The time interval between immunization and AEFI occurrence was mainly within 48 hours( 87. 21%). Conclusion The incidence of AEFI report in Dongtai City is higher than the national level,but the sensitivity of general response is not high. The balance of AEFI surveillance reports among regions and vaccines needs to be further improved.
Objective To analyze the distribution features of suspected adverse events following immunization( AEFI) from 2015 to 2017 in Dongtai City,Jiangsu Province,and to provide a basis for the scientific disposal of AEFI. Methods The AEFI report cases and vaccination data of Dongtai from 2015 to 2017 were analyzed in a descriptive approach. Results A total of 586 cases of AEFI were reported in Dongtai City from 2015 to 2017,with a reported incidence rate of 95. 05/100 000 doses. The timely rate that the interval of symptoms occurred until the investigation within 48 hours was 90. 96%. The AEFI report was concentrated in the second and third quarters,with the male-female ratio of 1. 37 ∶ 1 and the median age of 1. 54 years. The reported rates in different regions were between 0 and 258. 46/100 000 doses,and the reported incidence rate of AEFI about NIP vaccines was higher than that of other vaccines,and the reported incidence rate of each vaccine was significantly different. Of all the AEFIs,86. 18% were general reactions,and adverse events accounted for 12. 46%. The clinical symptoms were mainly fever,redness,swelling,induration and allergic rash. The reported rates were 53. 69/100 000 doses,35. 85/100 000 doses,17. 36/100 000 doses and 10. 87/100 000 doses,respectively. The time interval between immunization and AEFI occurrence was mainly within 48 hours( 87. 21%). Conclusion The incidence of AEFI report in Dongtai City is higher than the national level,but the sensitivity of general response is not high. The balance of AEFI surveillance reports among regions and vaccines needs to be further improved.
引文
[1]中华人民共和国卫生部.全国疑似预防接种异常反应监测方案[J].中国疫苗和免疫,2011,17(1):72-81.
[2]叶家楷,李克莉,许涤沙,等.中国2015年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2017,23(5):481-492,511.
[3]许涤沙,李克莉,武文娣,等.中国2016年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2018,24(3):299-309,322.
[4]陈敏,梁亚琼,徐鹭,等. 2013-2016年南京市疑似预防接种异常反应监测分析[J].现代预防医学,2017,44(23):4284-4288.
[5]许濒月,周颖,韩真明,等. 2011-2016年重庆市疑似预防接种异常反应监测分析[J].现代预防医学,2018(2):273-276,313.
[6]吴默秀,李锦阳,池益强,等. 2012-2014年厦门市百白破疫苗接种后异常反应监测分析[J].现代预防医学,2016,43(12):2244-2246,2258.
[7]韩一楠,杨月,林茜.大连市2011-2016年疑似预防接种异常反应监测分析[J].中国生物制品学杂志,2018,31(2):170-176.
[8]杨宏.中国2005-2012年疑似预防接种异常反应监测结果分析评价[D].北京:中国疾病预防控制中心,2014.
[9]武文娣,刘大卫,李克莉,等.中国2012年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2014,20(1):1-12,66.
[10]叶家楷,李克莉,许涤沙,等.中国2013年疑似预防接种异常反应信息管理系统数据分析[J].中国疫苗和免疫,2015,21(2):121-131,200.
[11]叶家楷,李克莉,许涤沙,等.中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J].中国疫苗和免疫,2016,22(2):125-137.
[2]叶家楷,李克莉,许涤沙,等.中国2015年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2017,23(5):481-492,511.
[3]许涤沙,李克莉,武文娣,等.中国2016年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2018,24(3):299-309,322.
[4]陈敏,梁亚琼,徐鹭,等. 2013-2016年南京市疑似预防接种异常反应监测分析[J].现代预防医学,2017,44(23):4284-4288.
[5]许濒月,周颖,韩真明,等. 2011-2016年重庆市疑似预防接种异常反应监测分析[J].现代预防医学,2018(2):273-276,313.
[6]吴默秀,李锦阳,池益强,等. 2012-2014年厦门市百白破疫苗接种后异常反应监测分析[J].现代预防医学,2016,43(12):2244-2246,2258.
[7]韩一楠,杨月,林茜.大连市2011-2016年疑似预防接种异常反应监测分析[J].中国生物制品学杂志,2018,31(2):170-176.
[8]杨宏.中国2005-2012年疑似预防接种异常反应监测结果分析评价[D].北京:中国疾病预防控制中心,2014.
[9]武文娣,刘大卫,李克莉,等.中国2012年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2014,20(1):1-12,66.
[10]叶家楷,李克莉,许涤沙,等.中国2013年疑似预防接种异常反应信息管理系统数据分析[J].中国疫苗和免疫,2015,21(2):121-131,200.
[11]叶家楷,李克莉,许涤沙,等.中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J].中国疫苗和免疫,2016,22(2):125-137.